About the BCNI
What is the BCNI?
BCNI is a national clinical research network that benefits blood cancer patients in Ireland. BCNI offers early stage clinical trials to blood cancer patients, offering the opportunity to test new, potentially life-saving treatments and drugs. BCNI is also establishing a biobank and blood cancer registry, which will further our knowledge and expertise in the field of blood cancer research and ultimately improve patient outcomes. BCNI is funded by the Irish Cancer Society and Science Foundation Ireland.
Who are the BCNI?
BCNI is a collaborative network of clinicians, scientists, and population health experts with a shared interest in blood cancer research. Members of the national network are based at the National University of Ireland, Galway/ University Hospital Galway, University College Cork/ Cork University Hospital, Trinity College Dublin/St James Hospital, The National Cancer Registry Ireland, Beaumont Hospital and The Mater. The key investigators involved are Professor Michael O’Dwyer, Professor Mary Cahill, Professor Paul Browne, Dr Eva Szegezdi, Professor Kerri Couugh-Gorr, Dr John Quinn and Professor Peter O'Gorman.
What we do?
Our aim is to provide Irish blood cancer patients with access to novel and innovative cancer treatments through the provision of early phase clinical trials. We will also collect information and samples from blood cancer patients in Ireland in order to improve our understanding and to uncover new ways to combat this disease.
Why we are novel and innovative?
The BCNI is bringing together clinical researchers in Cork, Dublin and Galway to form a national unit for carrying out early phase clinical trials in blood cancers. This national unit, combined with a dedicated biobank and patient registry, is creating a critical infrastructure making Ireland more competitive internationally in blood cancer research, which will enable us to attract more trials and ultimately lead to improvements in patient outcomes.
Our Industry Partners
BCNI has collaborations and research agreements with companies that are interested in developing new treatments for blood cancers and for supporting activities that will advance understanding of blood cancers. Our industry partners include:
- Bristol-Myers Squibb